AiZtech Labs has introduced its iSelfie BioSignals platform in the United States, positioning smartphone-based Vision AI as a tool to automate clinical intake and detect digital biomarkers. The solution uses a standard selfie-camera interaction to extract clinically relevant measurements from the eye and surrounding skin, with the aim of improving patient triage and reducing dependence on traditional hardware-intensive workflows.
The platform is designed to address operational challenges across the U.S. healthcare system, including workforce shortages, rising costs, and delays in patient access. By enabling early-stage assessment through a simple mobile interface, iSelfie BioSignals allows care teams to identify high-priority patients more efficiently while directing lower-acuity cases appropriately. This approach reduces the need for manual vital collection and supports faster decision-making at the point of entry into care.
Clinical validation has been conducted across more than 5,000 participants in six studies spanning the U.S., Canada, and other international markets. The technology has been applied to cardiovascular and respiratory use cases and has received regulatory clearance from the Saudi Food and Drug Authority for measuring heart rate, blood oxygen saturation (SpO2), and calibrated blood pressure.
Real-world deployment data from Saudi Arabia, including use during Hajj 2025, demonstrated measurable operational improvements. In the Makkah Al-Mukarramah Health Cluster, intake workflows were reduced from approximately seven minutes to two minutes per patient, contributing to an estimated $4.8 million in annual savings for one hospital network. The system was benchmarked against medical-grade measurements, confirming its performance in high-volume clinical environments.
Mohamed Sheta, co-founder and CEO of AiZtech Labs, stated that this “Vision AI infrastructure layer” is intended to replace the human-machine bottlenecks that have gated access to clinical decision-making for decades.
Following its presentation at HIMSS 2026, where more than 40 U.S. health systems expressed interest, AiZtech Labs is prioritizing partnerships with providers and population health organizations. The company aims to expand adoption in settings seeking scalable, low-friction alternatives to device-based intake processes, supporting broader efforts to digitize and modernize the initial stages of patient evaluation.
Click here for the original news story.
